| Market Capitalization (Millions $) |
97 |
| Shares
Outstanding (Millions) |
93 |
| Employees |
147 |
| Revenues (TTM) (Millions $) |
10 |
| Net Income (TTM) (Millions $) |
-148 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
4 |
Caribou Biosciences Inc
Caribou Biosciences Inc. is a biotechnology company that specializes in developing CRISPR-Cas9 gene editing technology. The company was founded in 2011 by Jennifer Doudna, Martin Jinek, Rachel Haurwitz, and Erik Sontheimer. Caribou Biosciences is headquartered in Berkeley, California.
The company focuses on leveraging CRISPR-Cas9 technology to enable precise and efficient gene editing in various applications, including therapeutics, agriculture, and industrial biotechnology. Caribou Biosciences offers a range of tools and services for genome engineering and is committed to providing reliable and scalable solutions.
Caribou Biosciences collaborates with academic institutions, pharmaceutical companies, and other partners to develop innovative treatments for genetic diseases, improve crop traits, and enhance bioproduction processes. The company's expertise in CRISPR-Cas9 has gained significant recognition within the scientific community, making Caribou Biosciences a leading player in the field of gene editing technology.
Company Address: 2929 7th Street Berkeley 94710 CA
Company Phone Number: 982-6030 Stock Exchange / Ticker: NASDAQ CRBU
|
50.45% 
94.52 %